Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Taysha Gene Therapies, Inc. Common Stock (TSHA)

Biological Products, (no Disgnostic Substances)

https://www.tayshagtx.com

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

3000 PEGASUS PARK DRIVE, SUITE 1430
DALLAS, TX

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/24/2020

Market Cap

458,047,605

Shares Outstanding

186,960,000

Weighted SO

186,960,193

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

BMEA --.--%

STOK --.--%

AKRO --.--%

FIXX --.--%

GOSS --.--%

XFOR --.--%

INZY --.--%

TERN --.--%

Beta

0.3890

Last Div

0.0000

Range

1.27-4.32

Chg

-0.0550

Avg Vol

2613982

Mkt Cap

458047605

Exch

NASDAQ

Country

US

Phone

214 612 0000

DCF Diff

2.3626

DCF

-0.1226

Div Yield

0.0000

P/S

35.5820

EV Multiple

-4.4673

P/FV

4.7797

Div Yield %

0.0000

P/E

-4.5512

PEG

-0.1820

Payout

0.0000

Current Ratio

5.2045

Quick Ratio

5.2045

Cash Ratio

5.0676

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

2407.0121

CCC

-2407.0121

Gross Margin

0.8973

Op Margin

-6.0340

Pretax Margin

-8.8818

Net Margin

-8.8818

Eff Tax Rate

0.0315

ROA

-0.5706

ROE

-2.4257

ROCE

-0.4673

NI/EBT

1.0000

EBT/EBIT

1.4719

EBIT/Rev

-6.0340

Debt Ratio

0.1976

D/E

0.3636

LT Debt/Cap

0.2579

Total Debt/Cap

0.2667

Int Coverage

102.7460

CF/Debt

-1.9042

Equity Multi

1.8407

Rec Turnover

0.0000

Pay Turnover

0.1516

Inv Turnover

0.0000

FA Turnover

0.6607

Asset Turnover

0.0642

OCF/Share

-0.3238

FCF/Share

-0.3404

Cash/Share

0.7439

OCF/Sales

-5.8561

FCF/OCF

1.0512

CF Coverage

-1.9042

ST Coverage

-42.9795

CapEx Coverage

-19.5402

Div&CapEx Cov

-19.5402

P/BV

4.7797

P/B

4.7797

P/S

35.5820

P/E

-4.5512

P/FCF

-5.7802

P/OCF

-6.9026

P/CF

-6.9026

PEG

-0.1820

P/S

35.5820

EV Multiple

-4.4673

P/FV

4.7797

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 29, 02:40 Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants The Motley Fool Jan 15, 09:30 3 Growth Stocks That Could Go Parabolic in 2024 Benzinga Nov 21, 06:30 Insiders Buying Taysha Gene Therapies And 3 Other Stocks Under $2 PennyStocks Nov 20, 14:03 Which Penny Stocks Are Best? 3 That Insiders Like In November PennyStocks Nov 20, 14:03 Which Penny Stocks Are Best? 3 That Insiders Like In November Benzinga Nov 15, 09:00 4 Analysts Have This to Say About Taysha Gene Therapies

Revenue Product Segmentation